with relatively low risk, and may help to identify the significant proportion of patients with septic shock and concomitant myocardial dysfunction or hypovolemia.

Christopher W. Seymour, MD, MSc
Matthew R. Rosengart, MD

Author Affiliations: University of Pittsburgh, CRISMA Center, Pittsburgh, Pennsylvania.

Corresponding Author: Christopher W. Seymour, MD, MSc, Departments of Critical Care Medicine and Emergency Medicine, University of Pittsburgh School of Medicine, 3550 Terrace St, Scaife Hall, Office 639, Pittsburgh, PA 15261 (seymourcw@upmc.edu).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Seymour received consulting fees from Beckman Coulter. No other disclosures were reported.


**CORRECTION**

Incomplete Dosage Information: In the article entitled “Evaluation and Treatment of Pericarditis: A Systematic Review” published in the October 13, 2015, issue of JAMA, Table 2 on page 1504 listed an incomplete dosage. The description of corticosteroid therapy should have read “Corticosteroids, 0.2-0.5 mg/kg per d.” This article was corrected online.


Value Errors in Tables and Abstract: The Rational Clinical Examination Systematic Review entitled “Does This Patient Have Posttraumatic Stress Disorder? Rational Clinical Examination Systematic Review” published in the August 4, 2015, issue of JAMA, had incorrect data in the Abstract, in Table 3, and in eAppendix S. In the Abstract, 2 sentences were removed and some values were rounded. The Trauma Screening Questionnaire row of Table 3 has an added footnote and the values for the Total Patients, PPV, and NPV columns should be 152, 44, and 89, respectively. In eAppendix S, there is an added footnote and the values for sensitivity, specificity, LR+, and LR− columns in the Trauma Screening Questionnaire row should be 0.95 (0.90-0.97), 0.26 (0.22-0.30), 1.3 (1.2-1.4), and 0.20 (0.10-0.40), respectively. This article was corrected online.


Incorrect Data in Tables and eFigure: In the Original Investigation entitled “Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial” published in the August 18, 2015, issue of JAMA, data were incorrect in the Tables and in the online eFigure 3. In Table 2, in the observed means row, the values shown in the Liraglutide columns (reported as −6.2, −4.8, −2.2) should have been reported as −5.9, −4.6, and −2.0, respectively; in addition, footnote “c” should have read “Number of participants not estimated.” In Table 3, in the “Increase” row in the “Change in net use of concomitant oral hypoglycemic agents” section, the first value in the Placebo column, reported as 7, should have been reported as 57. In panel “C” of eFigure 3 in the online Supplement, the value for placebo in the systolic blood pressure plot, reported as 1.2, should have been reported as 1.1. This article was corrected online.


**Guidelines for Letters**

Letters discussing a recent JAMA article should be submitted within 4 weeks of the article’s publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 7 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters being considered for publication ordinarily will be sent to the authors of the JAMA article, who will be given the opportunity to reply. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jama.com/public/InstructionsForAuthors.aspx. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at http://manuscripts.jama.com. For technical assistance, please contact jama-letters@jamanetwork.org.

Section Editor: Jody W. Zylke, MD, Deputy Editor.